Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-907-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin irritation / corrosion
Administrative data
- Endpoint:
- skin irritation: in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From July 28, 2017 to September 01, 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 439 (In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method)
- Deviations:
- yes
- Remarks:
- However, Guideline or SOP deviation was not considered to have affected the integrity or interpretation of the results as no equivocal results were obtained
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- [3-({4-carbamimidamido-1-[(1,3-dicarboxypropyl)carbamoyl]butyl}amino)-2-hydroxypropyl](dodecyl)dimethylazanium {3-[(1,3-dicarboxypropyl)amino]-2-hydroxypropyl}(dodecyl)dimethylazanium {3-[(4-carbamimidamido-1-carboxybutyl)amino]-2-hydroxypropyl}(dodecyl)dimethylazanium trichloride
- EC Number:
- 947-907-6
- Molecular formula:
- Molecular formula of major active constituents: C22H45Cl1N2O5 (representative for C12 alkyl chain quaternised glutamic acid) C23H50Cl1N5O3 (representative for C12 alkyl chain quaternised arginine) C28H57Cl1N6O6 (representative for C12 alkyl chain quaternised peptides of arginine and glutamic acid)
- IUPAC Name:
- [3-({4-carbamimidamido-1-[(1,3-dicarboxypropyl)carbamoyl]butyl}amino)-2-hydroxypropyl](dodecyl)dimethylazanium {3-[(1,3-dicarboxypropyl)amino]-2-hydroxypropyl}(dodecyl)dimethylazanium {3-[(4-carbamimidamido-1-carboxybutyl)amino]-2-hydroxypropyl}(dodecyl)dimethylazanium trichloride
- Test material form:
- other: paste
Constituent 1
In vitro test system
- Test system:
- human skin model
- Source species:
- human
- Cell type:
- non-transformed keratinocytes
- Cell source:
- other: Not specified
- Source strain:
- not specified
- Details on animal used as source of test system:
- The reconstructed human epidermal model EpiDermTM (EPI-200-MatTek Corporation) consists of normal human-derived epidermal keratinocytes which have been cultured to form a multi-layered highly differentiated model of the human epidermis. It consists of organised basal, spinous and granular layers and a multi-layered stratum corneum containing intercellular lamellar lipid layers arranged in patterns analogous to those found in vivo.
- Justification for test system used:
- Initially the predictive capacity of the modified EpiDerm™ Skin Irritation Test (SIT) test method, using MatTek EpiDermTM tissue model EPI-200, underwent full prospective validation from 2003-2007. The test method components of this method were used to define the essential test methods components of the original and updated ECVAM Performance Standards (PS). A modification of the original EpiDerm™ SIT was validated using the original ECVAM PS in 2008. In 2008, ESAC concluded that the Modified EpiDerm™ SIT has sufficient accuracy and reliability for prediction of R38 skin irritating and no-label (non-skin irritating) test substances.
- Vehicle:
- water
- Details on test system:
- Characterisation of the test system:
MatTek’s EpiDermTM model has been extensively characterised for multiple parameters including morphology, tissue viability, skin barrier function and sterility. QC results for the specific lot of models received (Lot# 25839) were checked in-house for MatTek acceptance ranges with following outcome:
Morphology - PASS
Tissue viability - PASS
Skin barrier function (ET50 value for 1% Triton X-100) where ET50 is the time taken for 1% Triton X-100 to reduce the viability of the skin model to 50% relative to the negative control)- PASS
Sterility testing showed no contamination during long term antibiotic and antimycotic free culture- PASS - Control samples:
- yes, concurrent negative control
- yes, concurrent positive control
- Amount/concentration applied:
- 25 mg (nominal) test substance (62.8% active)
- Duration of treatment / exposure:
- 60 ± 1 minute (25 minutes at room temperature and 35 minutes at 37°C, 5% CO2, ≥95% RH)
- Duration of post-treatment incubation (if applicable):
- 42 ± 4h
- Number of replicates:
- Three tissue replicates per condition
Results and discussion
In vitro
Results
- Irritation / corrosion parameter:
- % tissue viability
- Remarks:
- and c(Compared to the negative control)
- Run / experiment:
- Mean of 3 replicates
- Value:
- ca. 5.741
- Vehicle controls validity:
- not examined
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- positive indication of irritation
Any other information on results incl. tables
Results
Prior to the study, the required compatibility checks confirmed that the test substance did not interfere with MTT. However, water colouration was observed. Therefore, additional viable tissues were run without MTT to control for colouration (Colourant Controls/No MTT). The background levels of interference from this control was subtracted from the initial viability derived from the main test to give an adjusted overall viability.
Table 1: Results summary
|
Percentage of viability (relative to negative control) |
Classification Irritant (I)/non irritant (NI) |
Test substance |
5.741% |
Irritant (I) |
The test substance reduced the viability to below 50% and should be considered as Irritant to the skin.
Note that the final value was corrected after assessment of the colourant control.
Data Analysis:
Table 2: Viability measurements after 60 min (± 1min) of application and 46h (+9 mins) post-incubation of test and reference substances and controls
Condition |
Tissue # |
Raw data |
Blank corrected data |
Mean OD |
% of Viability |
||
Aliquot 1 |
Aliquot 2 |
Aliquot 1 |
Aliquot 2 |
||||
NC |
Tissue 1 |
1.911 |
1.865 |
1.737 |
1.691 |
1.714 |
105.0 |
Tissue 2 |
1.265 |
1.371 |
1.091 |
1.197 |
1.144 |
77.8 |
|
Tissue 3 |
1.856 |
1.595 |
1.682 |
1.421 |
1.552 |
95.0 |
|
PC |
Tissue 1 |
0.265 |
0.282 |
0.091 |
0.108 |
0.100 |
6.1 |
Tissue 2 |
0.232 |
0.232 |
0.058 |
0.058 |
0.058 |
3.6 |
|
Tissue 3 |
0.231 |
0.291 |
0.057 |
0.117 |
0.087 |
5.3 |
|
TA3 |
Tissue 1 |
0.304 |
0.303 |
0.130 |
0.129 |
0.130 |
8.0 |
Tissue 2 |
0.385 |
0.376 |
0.211 |
0.202 |
0.207 |
12.7 |
|
Tissue 3 |
0.286 |
0.288 |
0.112 |
0.114 |
0.113 |
6.9 |
NC: negative control (DPBS), PC: Positive control (SDS 5%), TA3: Test substance.
Note: Rounded figures used. NC tissue 2 was removed from further analysis as it was an outlier value as can be seen from the OD values and % viability.
Table 3: Mean and SD of cell viability measurements and of viability percentages after 60 min (± 1min) of application and 46h (+9 mins) post-incubation
Name |
Code |
Mean of OD |
SD of OD |
Mean of viability (%) |
SD of viability (%) |
CV % |
Classification |
DPBS |
NC |
1.633 |
0.115 |
100 |
7.036 |
7.036 |
Non-Irritant |
SDS 5% |
PC |
0.082 |
0.021 |
5.011 |
1.304 |
26.016 |
Irritant |
Test substance |
TA3 |
0.150 |
0.050 |
9.185 |
3.056 |
33.270 |
Irritant |
NC: Negative control (DPBS), PC: Positive control (SDS 5%), TA3: Test substance.
Prediction model of irritancy: test substances that reduce the viability to 50% or below are irritant (I), test substances with a percentage viability above 50% are considered to be non-irritant (NI).
Note: Rounded figures used.
Table 4: Mean % viabilities obtained from additional tests to correct for colourant interference
Test Substance |
Colourant Controls (CC/No MTT): % viability |
Initial % Viability |
Corrected % Viability |
TA3 |
3.444 |
9.185 |
5.741% |
TA3: Test substance.
Evaluation of the results
Results were checked against the following acceptance criteria:
|
Description |
Actual values |
PASS/FAIL |
Acceptance criterion 1 |
The mean OD570of the negative control (treated with DPBS) tissues is≥ 0.8 and ≤ 2.8 |
1.633 |
PASS |
Acceptance criterion 2 |
The mean of the positive control relative percentage viability must be ≤ 20% of the mean of the negative controls |
5.011 |
PASS |
Acceptance criterion 3 |
The standard deviation of OD values for triplicate skin models in each experimental condition must be < 18% |
NC: 7.036 PC: 1.304 TA3: 3.056 |
PASS |
Acceptance criterion 4 |
The mean OD of the 6 wells containing extraction solvent alone (blanks) should be ≤ 0.1 |
0.174 |
FAIL |
All acceptance criteria were met with the exception of criterion 4:
Optical Density (OD) values obtained with blanks were higher than 0.1 (0.174) causing a deviation from Acceptance Criteria 4. However, the spectrophotometer was fully validated and had passed all required tests. The OD values for blanks observed in this study are consistent with historical data using this spectrophotometer in the XCellR8 laboratory and meet laboratory internal acceptance criteria of blank OD values <0.194 (mean of XCellR8 historical data, based on blanks obtained during 66 historical runs), therefore this is not considered to be an issue in the interpretation of this study data. The study author concluded that this SOP and guideline deviation was not considered to have affected the integrity or interpretation of the results as no equivocal results were obtained.
Interpretation of results following Prediction Model
1) A test substance is considered to be an irritant (I) to skin in accordance with UN GHS Category 2 or EU R38 if the skin model viability after exposure and post-treatment incubation is ≤50%.
2) A test substance may be considered as a non-irritant (NI) if the skin model viability after exposure and post-treatment incubation is >50%.
The
final percentage of viability obtained with the test substance test
substance was
5.741%, therefore it was considered as Irritant to the skin.
Applicant's summary and conclusion
- Interpretation of results:
- other: Category 2 (irritant) based on EU CLP criteria
- Conclusions:
- Under study conditions, the test substance was determined to be irritating to the skin.
- Executive summary:
An in vitro study was conducted to determine the skin irritation potential of the test substance, 'Cocodimonium hydroxypropyl hydrolysed wool' (active: 62.8%) using Reconstructed Human Epidermis (RHE) test method, according to OECD Test Guideline 439, in compliance with GLP. EpiDermTM tissues were pre-incubated overnight at 37°C, 5% CO2, ≥95% relative humidity (RH), after which 30 µL test substance and reference substances (negative control: sterile Dulbecco’s phosphate buffered saline and positive control: sodium dodecyl sulphate (5% in water)) were applied topically for 60 ± 1 minute in triplicate, followed by rinsing steps and a 46 h + 9 mins post-dose incubation at 37°C, 5% CO2, ≥95% RH. Medium was changed on Day 2. MTT viability test was conducted and readings at 570 nm without reference filter were taken on Day 3. A test substance is considered to be an irritant to skin if the skin model viability after exposure and post-treatment incubation is ≤50%. Based on the results, the final percentage of viability obtained with the test substance was determined to be 5.741%; therefore it was considered as irritating to the skin. The Optical Density (OD) values obtained with blanks were higher than 0.1 (0.174) causing a deviation from Acceptance Criteria 4. The study author concluded that this deviation was not considered to have affected the integrity or interpretation of the results as no equivocal results were obtained. Hence, the study results qualified the acceptance criteria. Under the study conditions, the test substance was determined to be irritating to the skin (XCellR8, 2017).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.